Allan J. Pantuck, MD

Allan Pantuck, MD, MS, FACS

Professor, Department of Urology
Director of Translational Research, UCLA Kidney Cancer Program
Co-Director, Integrative Urology Program





Institutional Affiliation

Ronald Reagan UCLA Medical Center



Urology / Oncology, UCLA School of Medicine, 1999 - 2002


Surgery, Robert Wood Johnson University Hospital, Pediatrics, 1993 - 1995


MD, Robert Wood Johnson Medical School, 1993


Urology, Robert Wood Johnson University Hospital, Pediatrics, 1995 - 1999

Board Certification

Urology, American Board of Urology, 2004

Contact Information


(310) 794-7700 - Urology information and referral

Clinical Interests

Bladder Cancer, Cryosurgery, Gene Therapy, General Urology/Male, Hematuria, Kidney Cancer, Laser, Microwave Therapy For BPH, Nerve Sparing Prostatectomy, Oncology, Penile Cancer, Prostate Cancer, Prostate General, Prostate Nodules, Testicular Cancer, Urinary Diversion

Scientific Interests

Dr. Allan Pantuck's research focuses on the molecular and genetic determinants underlying response to immunotherapy in patients with kidney cancer, as well as the nutritional aspects of bladder and prostate cancer prevention and treatment.

Highlighted Publications

Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007; 13(2 Pt 2): 667s-670s.

Klatte T, Pantuck AJ. Editorial Comment on:"A Review on Follow-Up Strategies for Renal Cell Carcinoma after Nephrectomy" Eur Urol. 2007.

Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 2007; 13(2 Pt 2): 703s-708s.

Hung RJ, Zhang ZF, Rao JY, Pantuck A, Reuter VE, Heber D, Lu QY. Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol. 2006; 176(3): 1192-7.

Jin Y, Iwata KK, Belldegrun A, Figlin R, Pantuck A, Zhang ZF, Lieberman R, Rao J. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther. 2006; 5(7): 1754-63.